Predictive Oncology Inc. is focused on applying artificial intelligence (AI) to personalized medicine and drug discovery. It operates through its subsidiaries, Helomics Holding Corporation (Helomics), TumorGenesis Inc., Skyline Europe and Skyline Medical Inc. Helomics applies AI to its data gathered from patient tumors to both personalize cancer therapies for patients and focusses on the development of new-targeted therapies. Helomics’ clinical laboratory improvement amendments (CLIA)-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions. Its TumorGenesis Inc. is engaged in developing approach to tumors in the laboratory. Skyline Medical Inc. markets its STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions.